TY - JOUR
T1 - Insulin resistance and acanthosis nigricans
T2 - Evidence for a postbinding defect in vivo
AU - Cohen, Pinchas
AU - Harel, Chava
AU - Bergman, Reuven
AU - Daoud, Deeb
AU - Pam, Zeev
AU - Barzilai, Nir
AU - Armoni, Michal
AU - Karnieli, Eddy
N1 - Funding Information:
From the Metabolic Unit, Endocrine Institute, Departments of Internal Medicine C and Dermatology, Rambam Medical Center. and Faculty of Medicine, Technion, Haifa. Israel. Supported in part by a grant from the VS-israel Binational Foundation (No. 86-360) and the Andrea & Alfred Piker Memorial Fund. Dr Cohen'sp resent address is Department of Pediatrics, Stanford University Medical Center, Stanford, CA. Address reprint requests to Eddy Karnieli, MD, Metabolic Unit, Endocrine Institute, Rambam Medical Center, Haifa 31096. Israel. B 1990 by W.B. Saunders Company. 0026-0495/90/3910-0002$3.00/O
PY - 1990/10
Y1 - 1990/10
N2 - Acanthosis nigricans (AN) with insulin resistance has been traditionally attributed to insulin receptor abnormalities. To further clarify the postbinding defects of in vivo insulin action in this state, we applied the euglycemic insulin clamp technique, combined with the glucose trace infusion method, to 26 subjects: 12 AN patients (eight normoglycemic and four hyperglycemic), eight obese, and eight lean control subjects. The normoglycemic AN group exhibited fasting hyperinsulinemia (666% of control), 160% elevated hepatic glucose production (HGP), 425% increased posthepatic insulin delivery rate, and only slightly reduced (19%) insulin clearance rates, compared with controls. Except for the latter, all these abnormalities were statistically significant (P < .05), and could not be accounted for by body overweight. AN patients with diabetes mellitus (AN + DM) exhibited a further decreased insulin responsiveness (30%) and clearance (38%), together with a major increase in HGP (320%). All AN patients showed a significant right-shift in the insulin dose-response curve, indicating a decrease in insulin sensitivity. In conclusion, AN is characterized by increased basal rates of HGP, and peripheral insulin resistance, which can be partially attibuted to postbinding defects. In AN + DM, a worsening of these abnormalities may be responsible for unmasking the existence of diabetes.
AB - Acanthosis nigricans (AN) with insulin resistance has been traditionally attributed to insulin receptor abnormalities. To further clarify the postbinding defects of in vivo insulin action in this state, we applied the euglycemic insulin clamp technique, combined with the glucose trace infusion method, to 26 subjects: 12 AN patients (eight normoglycemic and four hyperglycemic), eight obese, and eight lean control subjects. The normoglycemic AN group exhibited fasting hyperinsulinemia (666% of control), 160% elevated hepatic glucose production (HGP), 425% increased posthepatic insulin delivery rate, and only slightly reduced (19%) insulin clearance rates, compared with controls. Except for the latter, all these abnormalities were statistically significant (P < .05), and could not be accounted for by body overweight. AN patients with diabetes mellitus (AN + DM) exhibited a further decreased insulin responsiveness (30%) and clearance (38%), together with a major increase in HGP (320%). All AN patients showed a significant right-shift in the insulin dose-response curve, indicating a decrease in insulin sensitivity. In conclusion, AN is characterized by increased basal rates of HGP, and peripheral insulin resistance, which can be partially attibuted to postbinding defects. In AN + DM, a worsening of these abnormalities may be responsible for unmasking the existence of diabetes.
UR - http://www.scopus.com/inward/record.url?scp=0025186279&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025186279&partnerID=8YFLogxK
U2 - 10.1016/0026-0495(90)90158-9
DO - 10.1016/0026-0495(90)90158-9
M3 - Article
C2 - 2215248
AN - SCOPUS:0025186279
SN - 0026-0495
VL - 39
SP - 1006
EP - 1011
JO - Metabolism: Clinical and Experimental
JF - Metabolism: Clinical and Experimental
IS - 10
ER -